What Xofigo Treats

Xofigo is a therapeutic radiopharmaceutical used in the management of advanced prostate cancer. Specifically, it is indicated for patients with metastatic castration-resistant prostate cancer (mCRPC) that has spread to the bones.

This treatment is intended for cases where the cancer is symptomatic, meaning it is causing bone pain or discomfort, and where there are no known metastases to internal organs like the liver or lungs. It is used when the cancer no longer responds to medical or surgical treatments that lower testosterone levels.

Main Uses

Bone-Metastatic Prostate Cancer

Prostate cancer cells often migrate to the skeletal system. Once these cells settle in the bone, they can cause significant damage to the bone structure. Xofigo is designed to target these specific areas of increased bone turnover. Because it mimics calcium, the substance is naturally absorbed by the bones at the sites where the cancer is active.

Targeted Alpha Therapy

As an alpha-emitting pharmaceutical, Xofigo delivers localized radiation directly to the bone metastases. The alpha particles have a very short range, which allows the treatment to focus its energy on the cancerous cells in the bone while limiting the exposure of surrounding healthy tissues and the bone marrow.

Benefits

Extension of Survival

The primary clinical benefit of this treatment is the potential to extend the life of patients with advanced prostate cancer that has spread to the bones. Clinical studies have demonstrated that it can increase overall survival compared to a placebo in patients with symptomatic mCRPC.

Reduction of Skeletal-Related Events

By targeting bone metastases, the treatment helps delay the occurrence of serious bone-related complications. These complications, often referred to as symptomatic skeletal events, include:

• Bone fractures (pathologic fractures)
• The need for radiation therapy to relieve bone pain
• Pressure on the spinal cord (spinal cord compression)
• The need for orthopedic surgery related to bone damage

Management of Bone Pain

Many patients with bone metastases experience chronic pain. By addressing the cancerous lesions within the bone, the treatment can help manage and reduce the pain associated with the spread of the disease, contributing to an improved physiological state during the course of the illness.

Eligibility Scope

Xofigo (Radium Ra 223 dichloride) is indicated for use only in adult men diagnosed with castration-resistant prostate cancer (CRPC). The medicine's use is strictly limited by regulatory authorities to patients who have symptomatic bone metastases and no known visceral metastatic disease (spread to internal organs).

---

Populations for whom use is contraindicated:

Contraindication Criterion	Regulatory Status
Pregnancy/Sex	Contraindicated in women who are pregnant or may become pregnant; not indicated for use in women.
Comedications	Contraindicated in combination with abiraterone acetate and prednisone/prednisolone (EMA, FDA).

---

Condition-Based and Age-Related Eligibility

Condition-specific Eligibility Rules:

• Hematologic Status: Before the first administration, patients must meet minimum blood count thresholds, including an Absolute Neutrophil Count ge 1.5 imes 10^9/ L and platelet count ge 100 imes 10^9/ L.
• Disease Extent: Use is not recommended for patients with only asymptomatic bone metastases or a low level of osteoblastic disease, as treatment benefit has not been established in these subgroups.
• Prior/Concurrent Therapy: Concomitant use with chemotherapy or other systemic radioisotopes is not recommended.

Age-Related Eligibility:

• The medicine is indicated for adults (age ge 18 years). Safety and efficacy have not been established in pediatric patients.
• Geriatric Use (ge 65 years): No dose adjustment is considered necessary in elderly patients (FDA, EMA).

This framework of regulatory eligibility ensures the medicine is used strictly within the patient population and clinical context for which it was formally approved by government health authorities.

Interactions with other medicines and products

The official regulatory documents define the interaction profile of Xofigo (Radium Ra 223 dichloride) through specific restrictions and documented pharmacodynamic effects, rather than metabolic pathways. As a radiopharmaceutical that decays and is primarily cleared through fecal excretion, Xofigo is not associated with clinically relevant pharmacokinetic interactions involving cytochrome P450 (CYP) enzymes or drug transporters. No interactions with food, alcohol, or herbal products are documented in official labeling.

---

Formal Restrictions and Contraindicated Combinations

The combination of Xofigo with abiraterone acetate and prednisone/prednisolone is formally contraindicated due to an observed increase in bone fractures and a trend toward increased mortality. If Xofigo treatment is initiated after a patient has completed this specific regimen, a regulatory timing rule requires that Xofigo must not be started for at least 5 days following the last administration of the abiraterone acetate combination.

---

Risk of Additive Pharmacodynamic Toxicity

Concomitant use of Xofigo with systemic cancer therapies other than LHRH analogues is not recommended due to the potential for an additive effect that increases the risk of myelosuppression (bone marrow toxicity). Furthermore, co-administration with bisphosphonates or denosumab may increase the documented risk of developing Osteonecrosis of the Jaw (ONJ), which is categorized as a pharmacodynamic interaction on bone tissue.

Calcium Mimicry: Selective Bone Targeting

The Radium-223 ion chemically mimics calcium, allowing it to be incorporated directly into the hydroxyapatite mineral matrix of the bone, particularly in areas exhibiting high bone turnover. This engages mechanisms that regulate mineral deposition, leading to the drug's focused accumulation. The resulting physiological effect is a highly concentrated delivery of the active substance to the direct microenvironment of cells adjacent to the concentration site, which is essential for the cytotoxic action.

Alpha Particle Cascade: High-LET Cytotoxicity

Once accumulated, Radium-223 releases high-energy, high-Linear Energy Transfer (LET) alpha particles during its decay chain. This high-LET radiation causes numerous, complex, and typically irreparable double-strand breaks in the DNA of adjacent cells. This is a mechanism of direct, non-repairable cellular damage that suppresses cell survival pathways, resulting in localized cellular destruction of the tumor and stromal cells.

Localized Action and Microenvironmental Disruption

The alpha particles have an extremely short range, penetrating only 2 to 10 cell diameters (less than 100 µm). This short range constrains the intense cytotoxic energy to the immediate vicinity of the radionuclide concentration. The resulting physiological effect is the highly localized suppression of cellular proliferation and disruption of the positive-feedback signaling between tumor and microenvironment cells.

Instruction Map: How to Use Xofigo — Official Administration Guidelines

Xofigo (radium Ra 223 dichloride) administration is governed by a controlled, cyclic protocol requiring specialized handling as a radiopharmaceutical.

Administration Scope	Detail
Route of administration	Intravenous (IV) injection only.
Dosing schedule	55 kBq (kilobecquerels) per kg body weight.
Timing in relation to meals	Not applicable (IV injection); no instructions regarding food or time of day.
Preparation requirements	Ready-to-use solution that must not be diluted or mixed with any other solutions.
Age-group administration rules	Older adults (aged 65 years): No dose adjustment is considered necessary. Pediatric patients: Safety and efficacy have not been studied.
Missed-dose rules	Treatment should be discontinued if hematologic values do not recover within 6 weeks after the last administration.
Special procedural conditions	Must be given as a slow IV injection over up to 1 minute. The line must be flushed with isotonic saline before and after injection.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Intravenous (IV) injection.
Frequency pattern	Cyclic/Intermittent — doses are administered at 4-week intervals.
Protocol basis	Dosing and schedule are established in standardized therapeutic protocols.
Use-context constraints	A maximum of 6 injections constitutes the full course of treatment, as safety and efficacy beyond this number have not been established.

---

Resulting Procedural Structure

Official step sequence:

• Dose Calculation: The patient's volume is calculated based on weight and the 55 kBq/kg dosage level, incorporating a decay correction factor.
• Hematological Verification: Blood counts must be measured before every dose to ensure specific hematological thresholds are met for the continuation of therapy.
• Dose Assay: The net patient dose must be verified in a calibrated radioisotope dose calibrator immediately before and after administration.
• Administration: The undiluted solution is administered via a slow IV injection with proper line flushing.

Connection to the overall use protocol (2–4 sentences): The official instructions establish a regulated, standardized protocol where the dose is customized to the patient's weight and delivered on a strict, four-week cyclical schedule. This process mandates specialized administration by authorized personnel and links the continuation of the treatment to procedural clearance based on periodic blood count verification. The entire course is limited to a maximum of six administrations.

Research evidence / Overview of studies for Xofigo

Evidence for Use in Castration-Resistant Prostate Cancer (CRPC)

The primary clinical evaluation of Xofigo was conducted using large, international Phase III randomized, double-blind, placebo-controlled clinical trials. The studies were applied in research contexts involving adult men whose prostate cancer had stopped responding to hormone therapy (castration-resistant) and had spread, presenting as symptomatic bone metastases, with no known spread to soft tissues or organs.

The main focus of these studies was to monitor Overall Survival (OS). Secondary outcomes examined included the Time to First Symptomatic Skeletal Event (SSE). This term refers to outcomes related to physical discomfort, specifically monitoring events such as the need for external beam radiation for skeletal pain or new bone fractures. Findings describe patterns observed related to these endpoints. Research describes group patterns, not personal outcomes; it contributes to understanding symptom patterns, but does not determine whether an individual will respond similarly.

---

Evaluation in Combination with Other Therapies

Research also examined the use of Xofigo alongside other treatment types, such as novel hormonal therapies. Trials exploring this use was associated with increased incidence of bone fracture and increased risk of death, which led regulatory bodies to place specific restrictions on this combination use. Findings describe patterns observed in the studies, which include evidence that contributes to understanding systemic or functional imbalance when these agents are combined.

---

What Is Still Uncertain About the Research for Xofigo

While the primary approval evidence is based on large, controlled trials, several areas of uncertainty and limitation exist in the broader research landscape: Long-term effects are not fully established, and the potential for rare, late-developing adverse effects remains the subject of ongoing observational studies. Subgroup findings are uncertain, as the research exploring outcomes in patients with a low volume of bone metastases (fewer than six lesions) provided inconsistent findings compared to the overall trial population.

Key Studies & References

1. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial (ALSYMPCA SSE endpoint)

Common questions about Xofigo (FAQ)

---

Q: How is Xofigo different from other radioactive treatments for prostate cancer?

Official product information states that Xofigo’s active ingredient, Radium-223, is an alpha particle emitter, which is a specific type of short-range radiation. The medicine is also known as a calcium-mimetic agent because it chemically mimics calcium. This unique property causes it to selectively target and accumulate in bone tissue, especially in areas with active cancer growth.

---

Q: Can Xofigo cause long-term side effects or health problems after treatment ends?

Regulatory documents mention a documented risk of secondary malignancies (new cancers), such as osteosarcoma. This risk is due to the long-term cumulative radiation exposure from the treatment. The possibility of long-term effects is generally considered by healthcare providers during follow-up.

---

Q: What is peripheral edema, and is it a common side effect of Xofigo?

Peripheral edema is swelling that typically occurs in the legs, ankles, or feet due to fluid accumulation. According to clinical trial data reported in official sources, this is listed as a Common side effect, meaning it was observed in at least 1 in 100 patients.

---

Q: What happens if blood test results are too low before a scheduled injection?

Before every injection, blood tests (haematological evaluation) are typically performed to check that cell counts meet the minimum regulatory thresholds. The official protocol states that if blood values do not recover within six weeks after the last administration, continuation of treatment is determined by the healthcare provider after a careful benefit and risk evaluation.

---

Q: Is it normal for a patient to stop Xofigo injections early if side effects are severe?

Official prescribing information indicates that treatment may be permanently discontinued if patients experience certain severe issues, such as unresolving bone marrow problems. The decision to interrupt or stop treatment early is a clinical judgment determined by the authorized healthcare provider based on the patient's clinical status.

---

Q: How does Xofigo compare to other bone-targeted agents like bisphosphonates (Zometa)?

Xofigo is an alpha-emitting radiopharmaceutical that delivers targeted radiation to bone metastases. In contrast, bisphosphonates (like Zometa) and denosumab are agents that modify bone structure. Regulatory documents note that using Xofigo with these other agents may be associated with an increased risk of Osteonecrosis of the Jaw (ONJ).

---

Q: Does Xofigo help with bone fracture prevention?

The main clinical studies examined the Time to First Symptomatic Skeletal Event (SSE), an endpoint that includes new bone fractures. Study results described an observed delay in the time it took for a bone fracture to occur in the Xofigo group compared to the placebo group.

---

Q: What kind of specialist typically administers Xofigo?

According to official safety regulations, Xofigo must only be handled and administered by authorized persons who are specifically qualified to use radioactive medicines. This process takes place in designated clinical settings to ensure radiation safety and correct administration.

---

Q: How long does Xofigo stay in the body after a treatment session?

The radioactive material, Radium-223, has a physical half-life of 11.4 days. Most of the administered dose is rapidly cleared from the body, with clinical data showing a median of 76% of the activity was excreted (mostly through the faecal route) by seven days after the injection.

---

Q: What symptoms are related to having low red or white blood cell counts while on Xofigo?

Patient counseling materials describe signs of low blood counts that patients may be asked to report, which may include feeling unusually tired or having shortness of breath (low red blood cells). Signs of low white blood cells or platelets can include fever or other signs of infection, or bleeding and bruising more easily.

---

Q: What is the definition of 'metastatic castration-resistant prostate cancer' (mCRPC)?

mCRPC is the medical term for prostate cancer that has spread to other parts of the body (metastatic), such as the bones. It is considered castration-resistant because the cancer continues to grow despite the patient's testosterone levels being lowered by medical or surgical treatment.

---

Q: Why is a decay correction factor used when calculating the Xofigo dose?

A decay correction factor is used in the dose calculation to account for the physical decay of Radium-223 over time. This factor is intended to provide the precise amount of radioactivity prescribed for the patient on the day of administration.

How to Store and Dispose of Xofigo

Storage and disposal of Xofigo (radium Ra 223 dichloride) are strictly regulated due to its classification as a radiopharmaceutical. All handling must be performed by authorized personnel.

Storage Conditions

Xofigo must be stored in its original container or equivalent radiation shielding at a temperature below 40°C (104°F), generally considered room temperature. The product must be kept out of the sight and reach of children.

Condition	Requirement
Temperature	Below 40°C (104°F)
Shelf Life (Post-Draw)	Limited to 96 hours at room temperature

Disposal

Unused product and all materials used for administration must be disposed of as radioactive waste according to local and national regulations. Following injection, patients should follow specified hygiene practices for approximately one week, including flushing the toilet several times after use, to limit potential exposure from bodily fluids.